GOUT FLARES & KRYSTEXXA
The pivotal clinical trials and a subsequent open-label extension study tracked the frequency of gout flares in patients taking KRYSTEXXA.
GOUT FLARES IN THE PIVOTAL CLINICAL TRIALS AND OPEN-LABEL EXTENSION (OLE)1,2
% of patients with at least 1 gout flare per 3-month period*
ADDITIONAL ENDPOINT + OLE DATA1,2
Reductions in the proportion of patients with gout flares and number of flares per patient during months 1-3 and 4-6 including OLE.
Investigators and patients were blinded to both treatment arm and sUA response. All patients continued to receive therapy regardless of sUA level1,4
*Pooled results of the ITT Population receiving pegloticase 8 mg by IV infusion every 2 weeks.1,2
- KRYSTEXXA (pegloticase) [prescribing information] Horizon.
- Becker MA, et al. Ann Rheum Dis. 2013;72:1469-1474.
- Sundy JS, et al. JAMA. 2011;306:711-720.
- Baraf HS, et al. J Clin Rheumatol. 2014;20:427-432.